Ewing Sarcoma of Bone Clinical Trial
Official title:
A Pilot Study of Chemotherapy Intensification by Adding Vincristine, Topotecan and Cyclophosphamide to Standard Chemotherapy Agents With an Interval Compression Schedule in Newly Diagnosed Patients With Localized Ewing Sarcoma Family of Tumors
This clinical trial is studying the side effects of combination chemotherapy and to see how well they work in treating patients with newly diagnosed localized Ewing sarcoma family of tumors. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving the drugs in different ways may kill more tumor cells.
PRIMARY OBJECTIVES:
I. To assess the feasibility and safety of adding interval-compressed vincristine, topotecan
hydrochloride, and cyclophosphamide to a treatment protocol utilizing interval compression
of vincristine, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide in
patients with localized Ewing sarcoma family of tumors.
SECONDARY OBJECTIVES:
I. To estimate the event-free survival in patients treated with this regimen.
OUTLINE: This is a multicenter study.
INDUCTION THERAPY (WEEKS 1-12): Patients receive vincristine IV on day 1 in weeks 1, 2, 5,
6, 9, 10, 11, and 12; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1 and
9; cyclophosphamide IV over 1 hour on days 1-5 in weeks 1 and 9 and on day 1 in weeks 5 and
11; ifosfamide IV over 1 hour on days 1-5 in weeks 3 and 7; etoposide IV over 1 hour on days
1-5 in weeks 3 and 7; and doxorubicin hydrochloride IV over 15 minutes on days 1 and 2 in
weeks 5 and 11. Patients also receive filgrastim (G-CSF) subcutaneously (SC) beginning 24-36
hours after the last dose of chemotherapy and continuing for at least 7 days or until blood
counts recover, whichever comes last. Filgrastim is discontinued at least 24 hours prior to
the next course of chemotherapy.
LOCAL CONTROL: Patients who respond to induction therapy may undergo surgery alone if the
lesion can be resected with negative margins and with a reasonable functional result
beginning in week 13. Following surgery, patients with unresectable lesions or inadequate
margins may receive radiotherapy during week 15. Patients with bulky lesions in surgically
difficult sites such as the spine, skull, and periacetabular pelvis; poor response to
induction chemotherapy; or those in whom surgery would result in unacceptable functional
results may receive radiotherapy alone in weeks 13-19. Patients with bulky lesions in
difficult sites and who do not have a good clinical and radiographic response to induction
therapy may receive radiotherapy to the primary site during weeks 13-19 followed by surgery
of the involved site during week 25 after recovery from course 11 of chemotherapy. Patients
with microscopic residual disease after planned pre-operative radiotherapy will receive
additional radiotherapy.
CONTINUATION THERAPY (WEEKS 15-36): Patients receive vincristine IV on day 1 in weeks 15,
16, 21-24, 27-30, 33, and 34; topotecan hydrochloride IV over 30 minutes on days 1-5 in
weeks 15, 21, and 29; cyclophosphamide IV over 1 hour on days 1-5 in weeks 15, 21 and 29 and
on day 1 in weeks 23, 27, and 33; ifosfamide IV over 1 hour on days 1-5 in weeks 17, 19, 25,
31, and 35; etoposide IV over 1 hour on days 1-5 in weeks 17, 19, 25, 31, and 35; and
doxorubicin hydrochloride IV over 15 minutes on days 1 and 2 of weeks 23, 27, and 33.
Patients also receive G-CSF SC as in induction therapy.
After completion of study treatment, patients are followed for 10 years.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06068075 -
Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD
|
N/A | |
Completed |
NCT03968471 -
Chemotherapy-induced Necrosis in Ewing Sarcoma
|
||
Completed |
NCT01825902 -
18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma
|
Early Phase 1 | |
Withdrawn |
NCT05116800 -
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
|
Phase 2 | |
Recruiting |
NCT04845893 -
Observational Study on Skeletal Ewing's Sarcoma
|
||
Withdrawn |
NCT01795430 -
Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma
|
N/A | |
Recruiting |
NCT05033288 -
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
|
||
Completed |
NCT00516295 -
Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma
|
Phase 2 | |
Completed |
NCT00674193 -
Evaluating Dactinomycin and Vincristine in Young Patients With Cancer
|
N/A | |
Completed |
NCT05024253 -
Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements.
|
Phase 3 | |
Recruiting |
NCT05395741 -
Regorafenib in Patients With Refractory Primary Bone Tumors
|
Phase 1/Phase 2 |